GLP-1s: Second year cost of care is $4,200 higher for patients with obesity
Individuals without diabetes who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for obesity experienced an average of $4,206...
top of page
Browse by category
Search
Skeletal muscle health concerns with the rise of weight loss medications
A commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically...
GLP-1 use doubles as bariatric surgery declines by 25%
A study by researchers at Brigham and Women's Hospital, in collaboration with researchers at Harvard TH Chan School of Public Health and...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events
Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...
GDF15 drug shows promise in preventing heart failure related to T2DM
A new experimental anti-obesity drug, Growth Differentiation Factor 15 (GDF15), improves diastolic heart function in mice with type 2...
Allurion submits 1st of three PMA modules to FDA
Allurion Technologies has submitted the first three modules of its premarket approval application (PMA) to the FDA for the Allurion...
Conversion from SG to Ring augmented RYGB is safe and effective
The first study to demonstrate the safety and effectiveness of a conversion from sleeve gastrectomy (SG) to a Ring-augmented Roux-en-Y...
FDA approves labelling update for VIVUS’ QSYMIA
The FDA has approved a labelling update for VIVUS’ QSYMIA (phentermine and topiramate extended-release capsules CIV) that has removed the...
Journal Watch 23/10/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
GLP-1 RAs may reduce opioid overdose risk by 40%
People with opioid or alcohol use disorder (OUD, AUD) who take glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to treat...
Browse by tag
bottom of page